HRMY
Harmony Biosciences Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.76
+0.44%Year over year
Reported trailing growth
- Revenue
- +24.3%
- EBITDA
- +4.3%
- EBIT
- +4.0%
- EPS
- -1.3%
- Free cash flow
- +37.2%
- Operating cash flow
- +36.9%
Forward estimates
Based on analyst estimates
- Revenue
- +19.4%
- EBITDA
- +13.2%
- EPS
- +26.6%
Three-year CAGR
- Revenue
- +25.6%
- EBITDA
- +20.2%
- EBIT
- +20.2%
- Net income
- -4.4%
- EPS
- -3.5%
- Free cash flow
- +34.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026